D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses ongoing research for patients with non–small cell lung cancer who harbor NRG1 fusions.
FDA Grants Breakthrough Therapy Designation to NVL-655 for Pretreated ALK+ NSCLC
Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection
FDA Grants Accelerated Approval to Tarlatamab for ES-SCLC
Danish Discusses the Benefits of SCINTIX Biology-Guided Radiotherapy in Metastatic Lung and Bone Cancers
OncLive’s April Roundup of Key FDA Decisions in Oncology
Applying the Heterogeneous Approach From NSCLC to SCLC
Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer
Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer
Addition of Denosumab to Neoadjuvant Chemo Does Not Lead to Significant iDFS Differences in Early Breast Cancer
Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer